Next Treatments
Back to Eczema

CGB-500 with tofacitinib

TypeTopical StagePhase 2 Latest updateOct 30, 2025Phase 2 study completed

History

Earliest recorded event: Dec 18, 2024. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Oct 30, 2025Phase 2 trial completedPhase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis ClinicalTrials.gov NCT06810050
  • Sep 30, 2025Phase 2 trial completedA Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis ClinicalTrials.gov NCT06923228
  • Aug 30, 2025Phase 2 main data collectedPhase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis ClinicalTrials.gov NCT06810050
  • Jul 30, 2025Phase 2 main data collectedA Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis ClinicalTrials.gov NCT06923228
  • Apr 21, 2025Phase 2 trial startedA Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis ClinicalTrials.gov NCT06923228
  • Dec 18, 2024Phase 2 trial startedPhase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis ClinicalTrials.gov NCT06810050

Sources

Trials